File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross-sectional study

TitleScreening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross-sectional study
Authors
Keywordsmethamphetamine
pulmonary hypertension
screening
Issue Date2019
PublisherBMJ Publishing Group: BMJ Open. The Journal's web site is located at http://bmjopen.bmj.com
Citation
BMJ Open, 2019, v. 9 n. 8, article no. e027193 How to Cite?
AbstractIntroduction Methamphetamine misuse is classified as a ‘likely’ risk factor for pulmonary arterial hypertension (PAH). Nevertheless, the actual prevalence of and a screening strategy for PAH in methamphetamine users have not been established. We plan to study the prevalence of PAH and identify its independent risk factors among methamphetamine users. Methods and analysis The Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA) study will be a multicentre, cross-sectional screening study that will involve substance abuse clinics, hospitals and rehabilitation facilities in Hong Kong that cater to more than 20 methamphetamine users. A total of 400 patients who (1) are ≥18 years at enrolment; (2) report methamphetamine use in the last 2 years; (3) are diagnosed with methamphetamine use disorder; and (4) voluntarily agree to participate by providing written informed consent will be included. Patients will undergo standard echocardiography-based PAH screening procedures recommended for those with systemic sclerosis. Right heart catheterisation will be offered to participants with intermediate or high echocardiographic probability of PAH. For participants with a low echocardiographic probability of PAH, rescreening will be performed within 1 year. The primary measure will be the prevalence of PAH in methamphetamine users. The secondary measures will be the risk factors and a prediction model for PAH in methamphetamine users.
Persistent Identifierhttp://hdl.handle.net/10722/274418
ISSN
2017 Impact Factor: 2.413
2015 SCImago Journal Rankings: 1.448

 

DC FieldValueLanguage
dc.contributor.authorCheng, Y-
dc.contributor.authorTung, CK-
dc.contributor.authorChung, KKA-
dc.contributor.authorLiu, W-
dc.contributor.authorHuang, D-
dc.contributor.authorChan, PHM-
dc.contributor.authorLam, M-
dc.contributor.authorChan, WC-
dc.contributor.authorSiu, CW-
dc.contributor.authorHai, SHJJ-
dc.date.accessioned2019-08-18T15:01:20Z-
dc.date.available2019-08-18T15:01:20Z-
dc.date.issued2019-
dc.identifier.citationBMJ Open, 2019, v. 9 n. 8, article no. e027193-
dc.identifier.issn2044-6055-
dc.identifier.urihttp://hdl.handle.net/10722/274418-
dc.description.abstractIntroduction Methamphetamine misuse is classified as a ‘likely’ risk factor for pulmonary arterial hypertension (PAH). Nevertheless, the actual prevalence of and a screening strategy for PAH in methamphetamine users have not been established. We plan to study the prevalence of PAH and identify its independent risk factors among methamphetamine users. Methods and analysis The Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA) study will be a multicentre, cross-sectional screening study that will involve substance abuse clinics, hospitals and rehabilitation facilities in Hong Kong that cater to more than 20 methamphetamine users. A total of 400 patients who (1) are ≥18 years at enrolment; (2) report methamphetamine use in the last 2 years; (3) are diagnosed with methamphetamine use disorder; and (4) voluntarily agree to participate by providing written informed consent will be included. Patients will undergo standard echocardiography-based PAH screening procedures recommended for those with systemic sclerosis. Right heart catheterisation will be offered to participants with intermediate or high echocardiographic probability of PAH. For participants with a low echocardiographic probability of PAH, rescreening will be performed within 1 year. The primary measure will be the prevalence of PAH in methamphetamine users. The secondary measures will be the risk factors and a prediction model for PAH in methamphetamine users.-
dc.languageeng-
dc.publisherBMJ Publishing Group: BMJ Open. The Journal's web site is located at http://bmjopen.bmj.com-
dc.relation.ispartofBMJ Open-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectmethamphetamine-
dc.subjectpulmonary hypertension-
dc.subjectscreening-
dc.titleScreening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross-sectional study-
dc.typeArticle-
dc.identifier.emailCheng, Y: yy520710@HKUCC-COM.hku.hk-
dc.identifier.emailChung, KKA: chungkka@hku.hk-
dc.identifier.emailHuang, D: huangduo@hku.hk-
dc.identifier.emailChan, PHM: phmchan@hku.hk-
dc.identifier.emailChan, WC: waicchan@hku.hk-
dc.identifier.emailHai, SHJJ: haishjj@hku.hk-
dc.identifier.authorityChung, KKA=rp02341-
dc.identifier.authorityChan, PHM=rp01864-
dc.identifier.authorityChan, WC=rp01687-
dc.identifier.authorityHai, SHJJ=rp02047-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1136/bmjopen-2018-027193-
dc.identifier.pmid31375608-
dc.identifier.scopuseid_2-s2.0-85070241230-
dc.identifier.hkuros302023-
dc.identifier.volume9-
dc.identifier.issue8-
dc.identifier.spagearticle no. e027193-
dc.identifier.epagearticle no. e027193-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats